These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 32985336)

  • 41. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Camporeale A; Tellapragada C; Kornijenko J; Nord CE; Giske CG
    Microbiol Spectr; 2021 Oct; 9(2):e0144021. PubMed ID: 34612686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Problems of
    Kiersnowska Z; Lemiech-Mirowska E; Ginter-Kramarczyk D; Kruszelnicka I; Michałkiewicz M; Marczak M
    Ann Agric Environ Med; 2021 Jun; 28(2):224-230. PubMed ID: 34184502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microbe-microbe interactions during Clostridioides difficile infection.
    Abbas A; Zackular JP
    Curr Opin Microbiol; 2020 Feb; 53():19-25. PubMed ID: 32088581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The long and sinuous road to phage-based therapy of
    Umansky AA; Fortier LC
    Front Med (Lausanne); 2023; 10():1259427. PubMed ID: 37680620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging alternatives against Clostridioides difficile infection.
    Romero-Rodríguez A; Martínez de la Peña C; Troncoso-Cotal S; Guzmán C; Sánchez S
    Anaerobe; 2022 Dec; 78():102638. PubMed ID: 36210608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics.
    van Werkhoven CH; Ducher A; Berkell M; Mysara M; Lammens C; Torre-Cisneros J; Rodríguez-Baño J; Herghea D; Cornely OA; Biehl LM; Bernard L; Dominguez-Luzon MA; Maraki S; Barraud O; Nica M; Jazmati N; Sablier-Gallis F; de Gunzburg J; Mentré F; Malhotra-Kumar S; Bonten MJM; Vehreschild MJGT;
    Nat Commun; 2021 Apr; 12(1):2240. PubMed ID: 33854064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In Vitro and In Vivo Anti-
    Islam MI; Seo H; Redwan A; Kim S; Lee S; Siddiquee M; Song HY
    J Microbiol Biotechnol; 2022 Jan; 32(1):46-55. PubMed ID: 34675143
    [No Abstract]   [Full Text] [Related]  

  • 49. Mechanisms of Colonization Resistance Against Clostridioides difficile.
    Pike CM; Theriot CM
    J Infect Dis; 2021 Jun; 223(12 Suppl 2):S194-S200. PubMed ID: 33326565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The microbial diversity following antibiotic treatment of Clostridioides difficile infection.
    Binyamin D; Nitzan O; Azrad M; Hamo Z; Koren O; Peretz A
    BMC Gastroenterol; 2021 Apr; 21(1):166. PubMed ID: 33849457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection.
    Sapkota M; Marreddy RKR; Wu X; Kumar M; Hurdle JG
    Anaerobe; 2020 Feb; 61():102129. PubMed ID: 31760080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Battling Enteropathogenic Clostridia: Phage Therapy for
    Venhorst J; van der Vossen JMBM; Agamennone V
    Front Microbiol; 2022; 13():891790. PubMed ID: 35770172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease.
    Gupta A; Wash C; Wu Y; Sorrentino D; Nguyen VQ
    Dig Dis Sci; 2021 Feb; 66(2):547-553. PubMed ID: 32207033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bacteriophages and bacteriophage-derived endolysins as potential therapeutics to combat Gram-positive spore forming bacteria.
    Nakonieczna A; Cooper CJ; Gryko R
    J Appl Microbiol; 2015 Sep; 119(3):620-31. PubMed ID: 26109320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial resistance in
    Imwattana K; Knight DR; Kullin B; Collins DA; Putsathit P; Kiratisin P; Riley TV
    Expert Rev Anti Infect Ther; 2020 Jan; 18(1):17-25. PubMed ID: 31800331
    [No Abstract]   [Full Text] [Related]  

  • 56. New treatment approaches for
    Bratkovič T; Zahirović A; Bizjak M; Rupnik M; Štrukelj B; Berlec A
    Gut Microbes; 2024; 16(1):2337312. PubMed ID: 38591915
    [No Abstract]   [Full Text] [Related]  

  • 57. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clostridioides difficile infection evaluation and management in the emergency department.
    Carius BM; Liang SY; Koyfman A; Long B
    Am J Emerg Med; 2020 Oct; 38(10):2203-2208. PubMed ID: 33071079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
    Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
    Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between Antibiotic Consumption and Incidence of
    Kim B; Kim J; Pai H
    J Korean Med Sci; 2020 Dec; 35(47):e407. PubMed ID: 33289370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.